secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0001193125-25-050334
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam reports positive initial Phase 1/2 data for BEAM-302 in AATD; total AAT exceeds protective threshold
--------------------------------------------------------------------------------

- BEAM-302 well tolerated at all doses; no serious AEs or dose-limiting toxicities observed.
- Single 60 mg dose achieved mean total AAT of 12.4 µM at Day 28, exceeding 11 µM protective threshold.
- Mutant Z-AAT reduced up to 78% from baseline at 60 mg dose level.
- First clinical evidence of precise genetic correction of a disease-causing mutation via base editing.
- Dose escalation to continue; further data expected at medical conference in H2 2025; Part B dosing planned H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000119312525050334/0001193125-25-050334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000119312525050334/d922493d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-050334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer